<DOC>
	<DOCNO>NCT02276547</DOCNO>
	<brief_summary>The purpose study evaluate safety initial performance Neovasc Tiara Mitral Transcatheter Heart Valve Tiara Transapical Delivery System .</brief_summary>
	<brief_title>Early Feasibility Study Neovasc Tiaraâ„¢ Mitral Valve System</brief_title>
	<detailed_description>This international , multicenter , single arm , prospective , Early Feasibility Clinical Study evaluate safety performance Neovasc Tiara Mitral Valve System subject symptomatic severe mitral regurgitation require mitral valve replacement high risk open chest surgery . A maximum 30 subject implant study maximum 10 site . A maximum 15 subject implant United States . Subjects satisfy inclusion criterion exclusion criterion enrol receive Neovasc Tiara Mitral Transcatheter Heart Valve Tiara Delivery System via transcatheter mitral valve replacement ( TMVR ) procedure .</detailed_description>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Severe symptomatic mitral regurgitation ( Stage D ) High surgical risk open mitral valve surgery Subject meet anatomical eligibility criterion available size ( ) NYHA Class III IV heart failure DMR deem heart team operable . Prohibitive risk , deem frail list cardiac transplant . Unsuitable cardiac structure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Mitral</keyword>
	<keyword>Regurgitation</keyword>
	<keyword>Heart valve</keyword>
	<keyword>Transcatheter</keyword>
	<keyword>Transapical</keyword>
	<keyword>Functional</keyword>
	<keyword>Degenerative</keyword>
	<keyword>Symptomatic , severe mitral valve regurgitation , high risk open mitral valve surgery</keyword>
</DOC>